MSD's immuno-cancer drug Keytruda has taken the lead in the domestic pharmaceutical market for the sixth consecutive period since the first quarter of last year. New drugs recently released by domestic and foreign pharmaceutical companies such as Perjeta, Prolia, and K-CAB are growing.

According to IQVIA, a pharmaceutical research firm on the 23rd, Keytruda recorded the highest sales of ₩93.3 billion in the first half of last year. It is up 29.% from the same period last year. Keytruda saw its sales rise 27.0% year-on-year to ₩44.1 billion in the first quarter, and continued its growth rate of 31.0% with sales of ₩49.2 billion in the second quarter.

Keytruda has topped the